Brainstorm Cell Therapeutics Inc. (BCLI)
NASDAQ: BCLI · Real-Time Price · USD
1.800
-0.060 (-3.23%)
Nov 4, 2024, 4:00 PM EST - Market closed
BCLI Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Current | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Nov '24 Nov 4, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Market Capitalization | 10 | 13 | 60 | 145 | 143 | 97 | |
Market Cap Growth | -66.82% | -77.69% | -58.70% | 1.59% | 47.63% | 31.62% | |
Enterprise Value | 7 | 15 | 57 | 123 | 116 | 97 | |
Last Close Price | 1.80 | 4.09 | 24.60 | 60.00 | 67.87 | 64.20 | |
PE Ratio | - | -0.68 | -2.47 | -5.88 | -4.25 | -4.03 | |
PB Ratio | -7.64 | -2.75 | -19.88 | 7.50 | 4.03 | -7.92 | |
P/FCF Ratio | -1.86 | -0.65 | -3.10 | -5.46 | -4.02 | -8.26 | |
P/OCF Ratio | -1.87 | -0.65 | -3.10 | -5.52 | -4.06 | -8.60 | |
EV/EBITDA Ratio | -1.70 | -0.70 | -2.32 | -5.06 | -3.67 | -4.26 | |
EV/EBIT Ratio | -1.67 | -0.69 | -2.29 | -5.00 | -3.65 | -4.23 | |
EV/FCF Ratio | -1.89 | -0.72 | -2.94 | -4.62 | -3.25 | -8.30 | |
Debt / Equity Ratio | -0.27 | -0.26 | -1.36 | 0.26 | 0.20 | -0.19 | |
Debt / FCF Ratio | -0.07 | -0.06 | -0.21 | -0.19 | -0.20 | -0.20 | |
Quick Ratio | 0.46 | 0.17 | 0.35 | 3.51 | 3.76 | 0.17 | |
Current Ratio | 0.50 | 0.24 | 0.35 | 3.69 | 3.85 | 0.19 | |
Return on Equity (ROE) | - | - | -297.38% | -89.25% | -273.75% | - | |
Return on Assets (ROA) | -178.20% | -211.70% | -82.24% | -38.09% | -68.53% | -161.87% | |
Return on Capital (ROIC) | - | - | -121.68% | -45.71% | -120.66% | - | |
Earnings Yield | -133.21% | -128.57% | -40.51% | -16.85% | -22.27% | -24.03% | |
FCF Yield | -151.11% | -153.13% | -32.29% | -18.33% | -24.90% | -12.11% | |
Buyback Yield / Dilution | -54.99% | -17.99% | -0.90% | -21.22% | -36.25% | -9.54% | |
Total Shareholder Return | -54.99% | -17.99% | -0.90% | -21.22% | -36.25% | -9.54% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.